Daiichi Sankyo
Tracked across 7 events · 123 articles · First seen Apr 21, 2022 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Daiichi Sankyo discovered Trastuzumab deruxtecan and jointly developed and commercialized it with AstraZeneca. The new approvals will lead to milestone payments from AstraZeneca and Daiichi Sankyo recognizes sales of Trastuzumab deruxtecan in the U.S.
May 15, 2026 · 16 articles
Business
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: Daiichi Sankyo is AstraZeneca's partner in developing Enhertu, which showed positive results in a lung cancer trial, providing a positive counterpoint to the volrustomig setback.
Aug 17, 2026 · 20 articles
Business
Impact: Daiichi Sankyo's stock was up, contributing to market gains.
May 21, 2026 · 40 articles
Regulatory
Impact: Daiichi Sankyo is reviewing its options regarding the United States — Medicaid pilot program, having missed the application deadline.
Apr 20, 2026 · 6 articles
Business
The Japanese stock market experienced a significant rally over several trading sessions in August 2026, with the Nikkei 225 index surging to record levels above 68,000. The rally was driven by strong gains in technology…
Impact: Daiichi Sankyo declined over 5%, underperforming the market.
Apr 21, 2022 · 26 articles
Business
Impact: Mentioned as a collaborator with AstraZeneca on Enhertu and Datroway, not directly impacted.
Jul 14, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Daiichi Sankyo live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard